Smith & Nephew Updates Share Capital and Voting Rights as of Year-End 2025

The latest update is out from Smith & Nephew Snats ( (SNN) ).

As of 31 December 2025, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,963,140 are held in treasury, leaving 849,761,705 ordinary shares with voting rights. The company stated on 2 January 2026 that this voting share count should be used by investors as the denominator when assessing whether they must disclose holdings or changes in holdings under the UK Financial Conduct Authority’s disclosure and transparency rules, clarifying the reference base for regulatory notifications and shareholder reporting obligations.

The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.

Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a UK-based medical technology company listed in the United States as a foreign private issuer. It operates in the healthcare sector, focusing on orthopaedics, sports medicine, and advanced wound management products for hospitals, clinics, and other healthcare providers globally.

Average Trading Volume: 565,279

Technical Sentiment Signal: Buy

Current Market Cap: $14.18B

Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.